At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Placebo +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Biological Activity of ATYR1940 in Adult Patients With Molecularly Defined Genetic Muscular Dystrophies
In Brief
A Phase 2 clinical trial evaluating Placebo and ATYR1940 for Facioscapulohumeral Muscular Dystrophy (FSHD). Completed, enrolled 20 participants across 5 sites in 4 countries.
Detailed Summary
The purpose of this study is to assess the safety and tolerability profile of ATYR1940 in the treatment of adult participants with molecularly defined genetic muscular dystrophies
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFrance, Italy, Netherlands, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartSep 2014
First PostedSep 2014
Primary CompletionDec 2015
TodayJul 2026
First PostedSep 12, 2014
Enrollment StartSep 4, 2014
Primary CompletionDec 14, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.8 years ago
Interventions
Placebobiological
Concentrate for solution for infusion
ATYR1940biological
Concentrate for solution for infusion